Positives

• A case report described two psoriasis patients on long-term secukinumab who rapidly recovered from COVID-19 between scheduled doses PMC.
  
  
• Adding a single 300 mg IV dose to baricitinib improved breathing function and survival in severe COVID pneumonia PMC.
  
  

Negatives

• Published reports center on acute COVID and psoriatic patients, not specifically Long COVID, leaving evidence thin PubMed.
  
  
• FAERS analysis flagged real-world adverse events including infections and inflammatory bowel disease flares Nature.
  
  

Hurdles & Side Effects

• Patient must self-inject every 4 weeks after loading and refrigerate the pen PubMed.
  
  
• A retrospective cohort during the omicron surge showed COVID still complicates SpA patients on secukinumab PubMed.